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1.1 - Abstract 
 
L-arginine is one of the most metabolically versatile amino acids in the human body. In its 
most extensively reviewed function, L-arginine serves as the pre-cursor for the biosynthesis 
of nitric oxide (NO), an essential substance in regulating vascular tone, triggering 
vasodilation and increasing blood flow. Despite conflicting literature, supplemental L-arginine 
may theoretically support general health and exercise capacity, through enhanced blood flow 
to tissues. While L-arginine supplementation has been compelling reported to improve 
exercise tolerance in patient populations, the findings in healthy and athletic populations are 
less consistent and often conflicting. Ergogenic effect has been demonstrated in previous 
literature, yet the supportive evidence-base is limited. Equally, a range of recent studies 
have reported no effect on exercise performance. The reported physiological effects of L-
arginine have served as the rationale behind the development and marketing of a number of 
NO stimulating dietary supplements. Such products profess to augment NO production, 
therefore improving blood flow to muscle during training, and in turn, leading to greater 
training adaptations. Consequently, supplementation with L-arginine and similar “NO 
boosters” has soared in popularity over the last decade, despite the fact that there is an 
overall lack of supportive data in healthy human cohorts, as ergogenic potential remains 
controversial and inconclusive. 
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1.2 – Introduction 
 
L-arginine is regarded as a semi-essential or conditionally essential amino acid (Morris, 
2006). It is one of the most metabolically versatile amino acids in the human body, 
demonstrated by its numerous important roles in a number of crucial physiological and 
biochemical processes (Morris, 2006). 
 
Indeed, L-arginine plays a number of significant functions within mammalian cells. For 
example, it plays a critical role in protein and creatine syntheses and in the biosynthesis of 
other amino acids (Campbell et al. 2006). Literature has also demonstrated L-arginine to 
play important roles in the secretion of growth hormone (HGH), augmenting the production 
of nitric oxide (NO) and in the regulation of the urea cycle. In the latter essential biochemical 
pathway, urea is synthesized from L-arginine to enable the body to remove excess 
ammonia, which is toxic to cells. (Campbell et al. 2006). 
 
A typical Western diet contains approximately 3–6 g of arginine per day, most of which is 
derived from plant proteins such as soy (Visek, as cited by Paddon-Jones, Borsheim & 
Wolfe, 2004), yet the rate of de novo synthesis remains unaffected by several days of an 
arginine free diet (Castillo et al., 1995). In humans, most endogenous L-arginine is derived 
from another amino acid, L-citrulline, which is a bi-product of glutamine metabolism 
(Appleton, 2006). As such, L-arginine can be synthesized within the human body as part of 
glutamine, glutamate, and proline metabolism (Appleton, 2006). The amino acid L-citrulline 
is recycled into L-arginine, after being produced during processes such as NO synthesis or 
glutamine metabolism, via a pathway termed ‘the Arginine-citrulline pathway’ (Figure 1) by 
Hecker et al. (as cited by Wu & Morris, 1998). 
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1.4 - L-Arginine Supplementation 
 
L-arginine is not considered an “essential” amino acid because humans can synthesize it “de 
novo” from glutamine, glutamate, and proline (Appleton, 2006). This means the body 
produces sufficient functional amounts on its own to meet most normal physiological 
demands, yet during times of stress or increased demand, for example, in exercise or 
disease, additional L-arginine is required from external dietary sources (Appleton, 2006). 
 
As such, despite the fact that L-arginine is already stored in significant intracellular amounts 
(Hambrecht et al. 2000), previous literature has indicated that L-arginine supplementation is 
associated with improvements in endothelial function, for example, increasing blood flow by 
increasing arterial diameter via NO-mediated vasodilation (Lerman et al. 1998). Hambrecht 
et al. (2000) stated that L-arginine supplementation increases endothelial substrate 
availability, in turn augmenting the synthesis of NO, as a result of the increased levels of L-
arginine as the substrate for NO synthesis. 
 
Support for this notion comes from Bailey et al. (2010) who observe that exogenous L-
arginine administration has previously been reported to increase urinary NO concentration 
(p<0.05, Maxwell et al., as cited by Bailey et al. 2010), plasma NO concentration (p<0.05, 
Xiao et al., as cited by Bailey et al. 2010), and L-citrulline concentration (p<0.05, Schaefer et 
al., as cited by Bailey et al. 2010), whilst reducing resting systolic blood pressure. 
Furthermore, an L-arginine-free diet has been demonstrated to reduce plasma NO 
concentration and synthesis, whilst also reducing L-arginine flux (Bailey et al. 2010). 
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Conversely, however, it has equally been suggested that L-arginine is ineffective in 
augmenting NO-mediated vasodilation (Tang et al. 2011). Tang et al. (2011) investigated the 
effects of an acute bolus of L-arginine on muscle blood flow and muscle protein synthesis in 
eight healthy young men (22.1 ± 2.6 y). Participants were recruited to two trials where they 
performed a single bout of resistance exercise (seated leg press) after consuming either a 
drink containing either 10 g essential amino acids (EAAs) with 10 g L-arginine, or a control 
beverage. Femoral artery blood flow was assessed using Doppler ultrasound, with results 
indicating that blood flow increased 270% above basal in the exercised leg but not in the 
non-exercised leg (Table 1) and intriguingly there was no differences between the L-arginine 
and control trials (p<0.001). As expected, L-arginine administration increased (p<0.001) 
plasma L-arginine levels; however, levels of plasma nitrate, nitrite, and endothelin-1, all 
markers of NO synthesis, did not change during either the ARG or CON trial, nor was there 
significant difference between the trials (p<0.001). Tang et al. (2011) concluded therefore 
that an oral, acute bolus of L-arginine does not increase NO synthesis, or consequently, 
muscle blood flow. 
Despite conflicting literature, according to Tong et al. (as cited in Campbell et al. 2006), 
supplemental L-arginine may, theoretically, support general health and capacity, through 
enhanced blood flow to tissues. This would potentially be beneficial to an athlete undergoing 
exercise training. 
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Table 1: Femoral artery blood flow in the non-exercised and resistance-exercise legs of young men during ARG 
and CON trials. (Redrawn from Tang et al. 2011). 
 
 
 
 
 
 
 
1.5 - L-Arginine and Pre-existing CVD 
 
The therapeutic, general health effects of L-arginine supplementation discussed by Tong et 
al. (as cited in Campbell et al. 2006), may also rationally apply to those populations whose 
health and ability to exercise was compromised by underlying pathology, such as in 
individuals with pre-existing cardiovascular disease including angina and atherosclerosis 
(Paddon-Jones et al. 2004). For example, Hambrecht et al. (2000) found beneficial effects 
on endothelial function and blood flow in people with chronic heart failure. It was reported 
that endothelial dysfunction, characterised by attenuated vasodilation and the presence of 
ischaemia (Hambrecht et al. 2000), was markedly improved following L-arginine 
supplementation, as a result of the aforementioned benefits on NO production. Forty patients 
with severe chronic heart failure were randomised into an L-arginine group (8g/day), a 
training group with daily forearm exercise training, or an inactive control group. It was 
observed that L-arginine supplementation had increased radial artery diameter from baseline 
(280 ± 33 vs 77 ± 5 µm) and therefore blood flow (p<0.001), demonstrating that 
10 
 
supplemental L-arginine is therefore also related to improved endothelial function in humans. 
Endothelial dysfunction is a marker of cardiovascular risk, and as such, L-arginine 
supplementation could potentially aid in reducing CV risk (Hambrecht et al. 2000; Wu & 
Meininger, 2000). 
 
Furthermore, clinical studies with L-arginine have also suggested beneficial counteraction to 
clinical ischemia (Ceremuzynski, Chamiec & Herbaczynska-Cedro, 1997). In a double-blind 
trial in 22 patients with healed myocardial infarction and stable angina, three-day oral 
supplementation of L-arginine (6g/day) was associated with enhanced exercise capacity 
(Ceremuzynski et al., 1997). Following three days L-arginine treatment, it was observed that 
maximum MET workload (ARG 7.4 ± 3 vs CON 6.4 ± 2, p<0.006) and time to maximal ST-
segment depression (p<0.04 were both significantly enhanced when compared to baseline 
data. This data suggests beneficial effects on ischaemia. Thus, according to Paddon-Jones 
et al. (2004), the anti-atherogenic and vasodilatory properties of L-arginine action appear to 
be indicative of improved exercise tolerance in patients with pre-existing CVD. 
 
Appleton (2006) reviewed and concluded that L-arginine supplementation appears to be a 
safe and effective therapy for many cardiovascular diseases which are responsive to 
modulation of nitric oxide, with the therapeutic effect thought to be as a result of improved 
NO-mediated vasodilation. 
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1.6 - Application to Exercise Performance 
 
The aforementioned biochemical and physiological effects of L-arginine would reasonably 
suggest that supplemental L-arginine could improve exercise performance (Campbell, La 
Bounty & Roberts, 2004), yet the available literature evidence is limited and conflicting 
(Paddon-Jones et al. 2004). An extensive summary of relevant literature related to L-arginine 
supplementation and exercise performance can be observed in Appendix 1.  
 
L-arginine supplementation has been associated with improved exercise capacity, in both 
healthy subjects (Campbell et al., 2006) and also in people with stable angina 
(Ceremuzynski et al., 1997). According to Lerman et al. (1998) improving endothelial 
function (i.e. NO-mediated vasodilator capacity via L-arginine supplementation) will increase 
blood flow. In theory, increasing blood flow will then in turn improve exercise performance 
via an increased rate of oxygen and substrate delivery (Tang et al. 2011), glucose uptake, 
and removal of waste exercise bi-products.  
 
This assumed relationship between blood flow and exercise performance was investigated in 
a recent study by Liu et al. (2010). Liu and colleagues observed the effects of acute L-
arginine supplementation on vasodilation and subsequent exercise performance in elite judo. 
Ten elite male college judo athletes completed two trials, with subjects receiving 6g/day L-
arginine or placebo for three days before undertaking an intermittent anaerobic cycling test. 
Pre-test, Liu et al. (2010) hypothesised that L-arginine supplementation would improve 
exercise performance as a result of enhanced NO-mediated vasodilation, concurrent with 
the aforementioned work of Lerman et al. (1998). Vasodilation was measured using 
photoplethysmography in pre-supplementation, pre-exercise, and at regular intervals post-
12 
 
exercise. Both conditions demonstrated exercise-induced vasodilation. However, L-arginine 
supplementation had no additional effect on exercise-induced vasodilation (ARG 32.8 ± 4.3 
vs CON 30.8 ± 4.0 % reflection index)  in these well-trained subjects (p<0.05). This study 
therefore suggested that the short-term arginine supplementation had no effect on exercise-
induced vasodilation and performance in intermittent anaerobic tests in well-trained male 
judo athletes. Liu et al. (2010) concluded that the lack of effect on performance was 
potentially as a consequence of the lack of L-arginine effect on NO-mediated vasodilation, 
thus highlighting the relationship between blood flow and exercise capacity. 
 
While L-arginine supplementation has been compellingly established to improve exercise 
tolerance in patient populations (Hambrecht et al. 2000; Ceremuzynski et al. 1997), the 
evidence in healthy humans is less consistent and often conflicting. Specifically, 
improvements in sprint performance (Buford & Koch, as cited in Bailey et al. 2010) and 
muscular power and fatigue resistance (Campbell et al. 2006) have been observed in 
studies following L-arginine supplementation, yet the supportive evidence-base is limited. 
Furthermore, an equal range of studies have indeed reported no effect on exercise 
performance (Liu et al. 2010). 
 
One study purporting the ergogenic potential of L-arginine supplementation was conducted 
in Brazil in 2002. Santos et al. (2002) aimed to evaluate the effect of oral supplemental L-
arginine on muscular fatigue during isokinetic exercise. Twelve healthy, untrained male 
volunteers consumed 3g of L-arginine daily over a 15 day period, before undergoing testing 
evaluating resistance to muscular fatigue via quadriceps isokinetic dynamometry. Data 
demonstrated that there was significant resistance to muscular fatigue following oral 
administration of L-arginine (10% and 7.6% respectively for left and right leg Fatigue 
Indexes), when compared to control baseline data (p<0.05). Santos et al. (2002) speculated 
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that these results may have been due to increased availability of nitric oxide and therefore 
the endothelium-dependent dilation, subsequently resulting in an increased muscular 
resistance to fatigue. Yet, although initially this study appears to provide substantial 
evidence for the beneficial effects of L-arginine supplementation, when evaluated by 
Campbell et al. (2004), the study was not deemed to be high quality due to the fact that the 
investigators had failed to utilize a double-blinded protocol or placebo group. 
 
An important, recent study conducted by Bailey et al. (2010) attempted to explore the 
hypothesis that acute L-arginine supplementation would elevate plasma NO levels, thus 
reducing systolic blood pressure and improving exercise capacity, as a result of enhanced 
NO bioavailability. In a double-blind study, nine healthy, recreationally active males (19-38 
years) took part in a supplementation and exercise testing program. They consumed a 500 
ml beverage containing 6g of L-arginine or a placebo beverage, before completing a series 
of moderate and severe intensity exercise bouts, 1 hour after ingestion of the beverage. This 
was repeated on seven occasions over a 4 to 5 week period. It was reported that plasma NO 
levels were significantly greater in the L-arginine group than in the placebo group (331 ± 198 
vs 159 ± 102 nM, p<0.05), whilst, as hypothesised, systolic blood pressure readings were 
significantly reduced (123 ± 3 vs 131 ± 5 mmHg, p<0.01). In terms of exercise performance, 
it was observed that dietary L-arginine supplementation reduced the oxygen cost of 
moderate intensity exercise by 7% (p<0.05) and extended the time to exhaustion (707 ± 232 
vs 562 ± 145 seconds, p<0.05) during severe-intensity exercise. Bailey et al. (2010) 
speculated that this is as a consequence of L-arginine supplementation elevating NO 
bioavailability, and the associated, discussed benefits of NO. 
 
The work of Bailey et al. (2010) provides rationale for the acute administration of L-arginine. 
As such, it is feasible to speculate that the acute oral ingestion of L-arginine may result in an 
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increase in NO synthesis and bioavailability, with corresponding physiological outcomes and 
effects on exercise capacity. However, as demonstrated, support for this concept is scarce, 
with the concept of acute supplementation providing a sizeable research gap. 
 
Supplemental L-arginine is often given in the form of arginine alpha keto-glutarate (AAKG), 
as this is seen to improve the bioavailability of L-arginine and therefore enhance any 
potential effects. Campbell et al. (2006) used this supplement format to assess the effects of 
AAKG on body composition, training adaptations and exercise performance in adult men. 
Thirty-five resistance trained men (30-50 years) were randomly assigned to ingest 
supplements, containing either a placebo or AAKG (12g/day) for an eight-week period of 
controlled, standardised training, during which, body composition and a series of exercise 
tests were performed at weeks 0, 4 and 8. Although, no significant differences were 
observed between the placebo and AAKG groups in terms of body composition; several 
training adaptations were observed in the AAKG group. Change in bench press 1RM over 
the eight weeks was significantly greater in the AAKG group (8.82 ± 7.33 vs 2.67 ± 9.11kg, 
p=0.03), whilst sprint peak power, time to peak power, and rate to fatigue were each 
significantly improved in the AAKG group (all, p<0.05). This formed the basis of the 
researchers’ conclusion that “AAKG supplementation may augment one-rep max strength, 
sprint power and rate to fatigue in response to training”. 
 
In contrast, AAKG has also been observed to have no effects on muscular endurance and 
blood pressure in trained college-aged men (Greer & Jones, 2011). Three sets each of chin-
ups, reverse chin-ups, and push-ups were performed to exhaustion with three minutes of 
rest between each set. AAKG supplementation did not improve muscle endurance or 
significantly affect the BP response to this anaerobic work (Greer & Jones, 2011). In fact, 
subjects performed fewer total chin-ups (AAKG 23.75 ± 6.38 vs. PLA 25.58 ± 7.18) and total 
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trial repetitions (AAKG 137.92 ± 28.18 vs. PLA 141.08 ± 28.57) in the supplement trial 
(p<0.05). 
 
As aforementioned, the work of Campbell et al. (2006) at Baylor University, Texas, was one 
of the early studies in healthy subjects to really push the ergogenic potential of L-arginine 
supplementation and formed the basis for the rationale that L-arginine supplementation 
could indeed be a worthwhile ergogenic aid for athletes. Intriguingly, however, five years 
later, as part of the same research group at Baylor University, Willoughby et al. (2011) 
provided evidence in direct contradiction to the earlier work of Campbell et al. (2006).  
 
Twenty-four healthy, resistance-trained men were recruited to ingest 12g/day for seven days 
in a double-blind design. The exact same dosage and ingestion protocols were used as 
earlier set out by Campbell et al. (2006). Prior to supplementation, subjects underwent 
baseline muscle strength testing, provided venous blood samples (pre-test, day 1 and day 
7), whilst brachial artery blood flow was assessed throughout the testing sessions via 
Doppler ultrasound (Willoughby et al. 2011). The testing sessions in questions consisted of 
standardised resistance-exercise in which subjects completed three sets of 15 repetitions at 
75% 1RM bicep-flexion exercise. 
 
In terms of hemodynamics, analysis revealed that although heart rate, systolic and diastolic 
blood pressure and MAP each increased significantly with the exercise protocol, there was 
no significant difference between the groups (p<0.05). Likewise, there was no difference 
(p=0.014) between ARG and PLA in terms of brachial-artery blood flow responses, which 
brings into question the very rationale of L-arginine ergogenics. Indeed, although plasma-L-
arginine significantly increased (p=0.001) in the ARG group (179.33 ± 75.79 vs 91.01 ± 
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16.27µmol/L), there was no significant difference between groups (p=0.073) in levels of 
serum NOx (nitrites/nitrates). 
 
There is a recent selection of literature in support of the findings of Willoughby et al. (2011). 
For example, it has been shown that single-doses of three separate alleged nitric-oxide-
inducing supplements (each containing L-arginine) were ineffective at increasing circulating 
nitric oxide levels and blood flow in response to resistance exercise (Bloomer et al. 2010). 
Similarly, work by Fahs, Heffernan & Fernhall (2009) observed that there was no significant 
change (p<0.05) in blood flow (Figure 2) or hemodynamic and vascular responses when 7g 
of L-arginine was given acutely, immediately before resistance exercise. 
 
 
 
 
 
 
 
Figure 2: Forearm blood flow responses pre and post resistance exercise. No significant difference (p<0.05) was 
observed between 7g ARG and PLA conditions (Fahs, Heffernan & Fernhall, 2009). 
 
Along these lines, work from Iran by Imanipour et al. (2011) also found L-arginine to be 
ineffective for increasing NO during intermittent anaerobic tests in elite male bodybuilders. 
30 matched weight bodybuilder consumed either 12g/day L-arginine or a placebo for six 
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A recent study did observe improved exercise performance in elderly cyclists following three-
weeks of L-arginine and antioxidant supplementation (Chen et al. 2010). Youthful, healthy, 
athletic individuals generally have a more efficient NO system, compared with aged 
individuals, with NO quantity and availability diminishing as we age (Taddel et al., as cited by 
Chen et al. 2010). Furthermore, exercise capacity declines with advancing age. The study 
subjects had an average age >55 years, suggesting lower baselines in vasodilatory capacity 
and exercise tolerance, which may explain the significant improvement on exercise 
performance (Chen et al. 2010). 
 
However, a particularly relevant recent study did concur that L-arginine could indeed provide 
a useful ergogenic aid in healthy subjects. Ranchordas & Whitehead (2011) investigated the 
effect of acute L-arginine on 20km time-trial performance in competitive male cyclists (n = 6, 
23 ± 5 years), in a double-blind, cross-over study. Subjects consumed either 500ml placebo 
(PLA) or L-arginine (ARG) beverage 6g L-arginine over a 3-day period. Following a 3-day 
supplementation, participants completed an incremental test to exhaustion, followed by a 
20km time trial. It was observed that time-trial completion time was significantly reduced 
(p<0.05) by 34 seconds (ARG 32:04 ± 1:38 vs PLA 32:38 ± 1:50 min), whilst O2 consumption 
and both systolic and diastolic blood pressure were also significantly reduced following ARG 
supplementation (all p<0.05). While these results seem to suggest ergogenic potential of 
acute L-arginine supplementation, unfortunately, the sample size (n = 6) was very small, and 
all cyclists were very well-trained, making it difficult to draw strong conclusions from this data 
as a consequence. 
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1.7 - Safety, Tolerance & Side Effects 
 
A recent review by Alvares et al. (2011) suggested that low oral doses are well tolerated and 
clinical side effects are rare in healthy subjects. Indeed, the majority of research within 
healthy subjects report tolerance to the consumption of L-arginine containing supplements. 
For example, in the work of Willoughby et al. (2011), participants reported by questionnaire 
that ingestion had been tolerated with no side effects. Campbell et al. (2006) concur that a 
daily dose as high as 12g appears safe and well tolerated. 
 
In contrast, however, consumption of L-arginine containing supplements has been 
associated with adverse effects on health (Prosser et al. 2009). Prosser et al. (2009) 
reported the cases of three patients, all of whom were admitted to hospital following the self-
reported use of L-arginine containing supplements. A 33-year-old man presented with 
palpitations, dizziness, vomiting, and syncope, after the use of NO2 Platinum. In addition, a 
21-year-old man with palpitations and near syncope had used a "nitric oxide" supplement, 
whilst a 24-year-old man presented after taking NO-Xplode with palpitations and a 
headache. According to Prosser et al. (2009), the purported active ingredient in each of 
these products is L-arginine, and therefore consumption of L-arginine containing 
supplements may be associated with adverse effects on health, adding a further element of 
doubt regarding the necessity of L-arginine supplementation in healthy subjects. 
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1.8 – Concluding Remarks 
 
The reported physiological and biochemical effects of L-arginine have served as the 
rationale behind the development and marketing of a number of NO stimulating dietary 
supplements to elite athletes (Campbell et al. 2006). Such supplements profess to augment 
NO production, therefore improving blood flow to muscle during training, and in turn, leading 
to greater training adaptations. Consequently, in recent years, professional sports individuals 
have begun to use L-arginine supplementation prior to competition as an ergogenic aid. 
Indeed, supplementation with L-arginine and similar “NO boosters” has soared in popularity 
over the last decade (Campbell et al. 2006), despite the fact that there is an overall lack of 
supportive data in healthy human cohorts, as ergogenic potential remains controversial and 
inconclusive (Bailey et al. 2010; Liu et al. 2010).  
 
As demonstrated, there is a wealth of evidence exploring the ergogenic potential of L-
arginine supplementation for improved exercise performance. The findings in healthy 
humans seem inconsistent and often conflicting. Specifically, improvements in sprint 
performance (Buford & Koch, as cited in Bailey et al. 2010), time to exhaustion (Bailey et al. 
2010), cycling time trial performance (Ranchordas & Whitehead, 2011), muscular power and 
fatigue resistance (Campbell et al. 2006) have each been observed in studies following L-
arginine supplementation, yet the supportive evidence-base is limited and conflicted. 
Equally, supplementation with L-arginine has been shown to be ineffective in improving 
muscular endurance and resistance to fatigue (Wax et al. 2012; Greer & Jones, 2011; 
Willoughby et al. 2011).  
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The possible adverse health effects (Prosser et al. (2009) should not be neglected or 
minimalised, however, in an industry where the margins between success and failure can be 
incredibly small, it is feasible to suggest that any potential benefit to athletes provided by L-
arginine should be considered worthwhile.  
 
1.9 – Rationale for Further Research 
 
As demonstrated, the ergogenic potential of L-arginine-based supplementation remains 
equivocal in the literature, and the need for further research is therefore well established. 
Experimentation with higher dosages, perhaps as high as 30g as hypothesised by Bode-
Boger et al. (1998) may be justified. However, concerns with tolerance and aforementioned 
side effects may arise. 
 
In addition, research into different supplementation protocols may be warranted. As many L-
arginine containing sports products are marketed as ‘pre-trainers’ and ‘NO-boosters’ 
(Campbell et al. 2006), it is problematic that the rationale for acute supplementation should 
provide such a sizeable research gap. Indeed, it does appear that industry instructions to 
ingest L-arginine before exercise are supported by little evidence (Greer & Jones, 2011). 
Only a handful of studies have adopted this ingestion protocol, and the data is inconsistent in 
terms of ergogenic effect (Ranchordas & Whitehead, 2011) and no effect (Greer & Jones, 
2011; Wax et al. 2012). Further research into the ergogenic effects of acute doses of L-
arginine prior to an exercise bout is therefore justified. 
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Appendix 1 
Literature Review Summary Table: The effects of L-arginine supplementation on exercise performance 
 
 
 
Researchers 
 
 
Subjects 
 
Supplementation 
Protocol 
 
Methodology 
 
Ergogenic 
Effects? 
 
Results 
 
Concluding 
Remarks 
 
 
Critique 
Bailey et al. (2010) 
University of Exeter 
n = 9 
Recreationally 
active young men 
(26 ±6yr) 
6g Arg once daily (1hour 
pre-test) for 3 days of 
testing (no caffeine or 
alcohol for 24h) 
 
10 day washout period 
Moderate intensity 
cycling & high intensity 
cycling to fatigue (over 
3 consecutive days) 
 
 
✓ 
Plasma NO2 was increased (ARG 
331±198 vs PL 159±102nM, p<0.05). 
Systolic BP was reduced (ARG 123±3 
vs PL 131±5mmHg, p<0.05). 
Time to exhaustion was extended 
(ARG 707±232 vs PL 562±145s, 
p<0.05). 
O2 consumption was reduced (ARG 
1.48±0.12 vs PL 1.59±0.14l/min, 
p<0.05). 
“Arg significantly 
increased plasma 
NO2, reduced systolic 
BP and resulted in 
reduced O2 cost and 
improved time to 
fatigue in 
moderate/high 
intensity exercise” 
Supplement 
composition (ARK – 
containing vitamins, 
other amino acids 
and fructose) 
Campbell et al. 
(2006) 
Baylor University, 
USA 
n = 20 ARG 
n = 15 PLA 
Resistance trained 
adult men 
(38.9±5.9yr) 
Four caplets AAKG, three 
times per day (12 caplets 
= 6g per day) for eight 
weeks 
 
IOC certified supplement 
4 days/week 
resistance training 
programme and 70% 
max aerobic work 3 
days/week for a total 
of 8 weeks.  
 
Recorded reps & 
weights on training 
cards 
 
 
 
✓ 
Significant difference in 1RM bench 
press performance (AAKG 8.82±7.33 
vs PLA 2.67±9.11, p=0.03) 
Significant positive effects on Wingate 
peak power performance. 
No significant effects on aerobic 
capacity variables (time to 
exhaustion, O2 consumption), BP or 
body composition. 
“AAKG 
supplementation 
appeared safe and 
well tolerated, and 
positively influenced 
1RM bench press and 
Wingate peak power 
performance. AAKG 
did not influence body 
composition or aerobic 
capacity” 
Sponsored by 
relevant nutrition 
facility (Medical 
Research Institute, 
San Francisco) who 
provided 
supplement 
 
Older subjects 
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Chen et al. (2010) 
UCLA, USA 
n = 8 ARG 
n = 8 PLA 
Sixteen ‘elderly’ 
male cyclists (50-
73yr) 
5.2g ARG once daily 
before bed over a 3 week 
testing period 
Each serving contained 
5.2 g L-arginine with L-
citrulline, ascorbic acid, 
vitamin E, folic acid, L-
taurine) 
Incremental cycle 
ergometer test to 
fatigue 
 
Constant work rate 
test at 60% max 
 
 
✓ 
Anaerobic threshold significantly 
increased in Arg group: by 16.7% at 
week 1, and the effect was sustained by 
week 3 with a 
14.2%. In the control group, there was 
no change in anaerobic threshold at 
weeks 1 and 3 compared to baseline. 
The anaerobic threshold for the 
supplement groups was significantly 
higher than that of placebo group. 
“An arginine 
containing supplement 
increased the 
anaerobic threshold in 
elderly cyclists. This 
study indicates a 
potential role of L-
arginine and 
antioxidant 
supplementation in 
improving exercise 
performance in 
elderly” 
Low applicability to 
younger subjects 
(impaired NO 
production & 
exercise capacity) 
 
Supplement 
composition 
Ranchordas & 
Whitehead (2011) 
Sheffield Hallam 
University 
n = 6 
Male competitive 
cyclists (23±5yr) 
6g Arg once daily for 3 
days preceding testing 
 
10 day washout period 
Incremental cycle test 
to fatigue followed by 
1 hour rest and 20km 
time trial. 
 
✓ 
Time trial completion time was 
reduced by 34s (PLA 32.38±1.50 vs 
ARG 32.04±1.38m, p<0.05). 
O2 consumption reduced (PLA 
51.6±8.2 vs ARG 47.5±6.1ml/kg/min, 
p<0.05). 
Both systolic & diastolic BP reduced 
(PLA 132±7 vs ARG 127±7mmHg, 
p<0.05 and PLA 79±5 vs ARG 74±5mm 
Hg, p<0.05). 
 
“L-arg 
supplementation at a 
dose of 6g/day 
increases 20km time 
trial performance, 
reduces O2 
consumption and 
reduces systolic and 
diastolic BP” 
Small sample size 
Tang et al. (2011) 
McMaster 
University, Canada 
n = 8 
Recreationally 
active males 
(22.1±2.6 yr) 
 
 
10g Arg as part of a post-
exercise beverage  
Seated leg press and 
knee extension 
resistance exercise – 
Single leg only 
 
 
X 
Plasma endothlein-1, nitrate, and nitrite 
concentrations were unchanged, with 
no difference between ARG and 
CON. 
 
Following the bout of exercise, femoral 
artery blood flow increased ~270% 
above basal in the exercised leg but not 
in the non-exercised leg, with no 
difference between ARG & CON. 
 
Muscle protein synthesis greater in the 
exercised leg than non-exercised leg, 
with no difference between ARG & 
CON. 
“Despite a 4-fold 
increase in plasma 
levels, arginine 
supplementation does 
not stimulate an 
increase in NO 
synthesis or muscle 
blood flow in young 
men at rest or after 
resistance exercise, 
questioning the 
ergogenic potential of 
arginine in healthy 
young men” 
Novel approach for 
use of Arg as a post-
exercise supplement 
24 
 
Liu et al. (2010) 
National College of 
Physical Education, 
Taiwan 
n = 10 
Elite male judo 
athletes (20.2±0.6 
yr) 
6g Arg/day for two days 
pre-testing with final dose 
of 6g 1 hour pre-test 
 
4 day washout period 
Intermittent anaerobic 
exercise test. 
Alternated 20-sec all-
out exercise and 15-
sec rest periods for 13 
sets cycle ergometer. 
Designed to mimic the 
actual judo 
competition. 
 
 
X 
No significant difference in peak power 
(ARG: 29.0±4.9%; CON: 35.1±4.5%) 
and average power (ARG: 28.0±4.3%; 
CON: 28.6±3.4%). 
 
No significant difference was found 
between the ARG (85.0 ± 3.6%) and 
CON (83.6 ± 2.9 %) trials before 
exercise for Vascular Reflection Index 
(a measure of vasodilation). 
“The results of this 
study suggested that 
short-term arginine 
supplementation had 
no effect on exercise-
induced vasodilation 
and performance in 
intermittent anaerobic 
exercise in well-
trained male judo 
athletes” 
Potential low 
applicable to 
Western athletic diet 
Greer & Jones 
(2011) 
Sacred Heart 
University, USA 
n = 12 
Trained college 
male athletes 
(22.6 ±3.8yr) 
3700mg AAKG 4 hours 
and again 30 minutes 
before exercise (no 
caffeine on day of testing) 
 
7 day washout period 
 
Three sets each of 
chin-ups, reverse chin 
ups and push ups to 
exhaustion with 3 mins 
rest between sets 
 
 
X 
No effect on chin-up repetitions 
(AAKG 23.75±6.38 vs PL 25.58±7.18). 
No effects on total repetitions (AAKG 
137.92±28.18 vs PL 141.08±28.57). 
No effects on BP 
“Arg had no positive 
ergogenic benefit and 
may acutely be 
counterproductive for 
muscular endurance” 
“Because AAKG may 
hinder muscular 
endurance, the use 
before resistance 
training should be 
questioned” 
Supplement quality 
control – Ingredients 
not tested (cited as 
a potential 
confounder by 
authors) 
Santos et al. (2002) 
University of 
Paraiba Valley, 
Brazil 
 
n = 12 
Healthy male 
volunteers 
(23.8±3.5yr 
3g Arg (1.5g twice a day) 
daily for 15 days during 
testing period. 
Five minute, 
cardiovascular warm-
up and stretching 
followed by 15 
repetitions of isokinetic 
knee extension & 
flexion. 
 
✓ 
Significant difference between control 
(no beverage) and ARG condition for 
various fatigue indices and fatigue 
resistance factor (FRF). 
“Treatment  by oral 
arginine leads to an 
increase in the 
capacity of resistance 
to muscular fatigue” 
 
Single-blind design 
Wax et al. 
(2012) 
Missisippi State 
University, USA 
n = 16 
Eight resistance-
trained, eight 
untrained 
(19.8 ± 1.9 yr) 
 
3000mg AAKG or placebo: 
45 minutes prior to a 
resistance exercise 
protocol. 
Following the 
determination of one 
repetition maximum 
(1RM), subjects 
completed repetitions 
to failure at 60% 1RM 
on both barbell bench 
press and leg press. 
 
 
X 
No significant difference (P<0.05) in 
bench press or leg press performance 
between AAKG or PLA conditions for 
either 1RM of total load volume, 
regardless of the training status of the 
subjects. 
“Acute AAKG 
supplementation 
provided no ergogenic 
benefit, regardless of 
the subject’s training 
status..... and AAKG is 
therefore not 
recommended for 
healthy individuals”  
Supplement quality 
control – Ingredients 
not tested (cited as 
a potential 
confounder by 
authors) 
 
Groups determined 
by self-reported 
training status. 
Significant 
differences between 
the groups at 
baseline. 
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Rationale for Journal Publication 
 
A potential target journal for publication of this work would be The Journal of Strength & 
Conditioning Research (JSCR). The JSCR pledges to “advance the knowledge and 
understanding of conditioning and sport through applied exercise science” and, according to 
the 2011 ISI Citation Report, is ranked in the top 30 journals in the field of Sport & Exercise 
Science. A unique aspect of this journal is that it includes recommendations for the practical 
applications of research findings, allowing the front-line sports practitioner to immediately 
benefit from contemporary findings. With a relatively successful Impact Factor of 1.831, and 
a proven track record in the subject area (a literature search shows that four relevant studies 
regarding arginine ingestion and exercise performance have been published in the journal 
since 2010), the JSCR appears a feasible choice for potential publication. 
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Abstract 
Introduction: L-arginine is one of the most metabolically versatile amino acids in the 
human body, most notably serving as the pre-cursor for the biosynthesis of nitric oxide 
(NO). The reported physiological effects of L-arginine have served as the rationale 
behind the development and marketing of a number of NO stimulating dietary 
supplements, which profess to augment NO production and improve blood flow to 
muscle during exercise. Supplementation with L-arginine and similar “NO boosters” has 
soared in popularity over the last decade, despite the fact that there is an overall lack of 
supportive data in healthy humans, as ergogenic potential remains inconclusive. The 
aim of this study was therefore to determine the effects of acute supplementation of 
commercially available L-arginine on exercise performance.  
Methods: Twelve recreationally trained, young adult males (22.3 ± 4.1 yr, 79.3 ± 7.9 kg, 
180.9 ± 2.3 cm) consumed either: a placebo (PLA), an L-arginine beverage containing 
8g L-arginine (ARG) or no beverage (CON) in a double-blind, repeated-measures 
design. 45 minutes following consumption, participants completed a 10 mile time trial on 
a cycle ergometer.  
Results: There was no significant difference (p=0.643) in time-trial performance 
between the conditions (CON 29:49 ± 2:19 vs ARG 29:49 ± 3:18 vs PLA 29:30 ± 2:42 
minutes). There was no significant difference (p=0.276) between conditions in volitional 
power output (W) (CON 119.3 ± 8.7 vs ARG 120.1 ± 7.7 vs PLA 121.2 ± 6.2 W), or in 
heart rate responses (p=0.129) (CON 169.2 ± 11.3 vs ARG 167.2 ± 10.8 vs PLA 166.3 ± 
7.8 bpm). Significant differences (p=0.033) were observed between conditions (CON 
15.6 ± 1.6 vs ARG 15.2 ± 2.0 vs PLA 15.0 ± 1.7) in RPE responses.  
Conclusions: With no ergogenic benefits observed in this study, the rationale for pre-
exercise supplementation with arginine may be further brought into question. 
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Introduction 
 
L-arginine is one of the most metabolically versatile amino acids in the human body, 
featuring in a number of crucial physiological and biochemical processes (Morris, 2006). In 
its most extensively reviewed role, L-arginine serves as the precursor for the biosynthesis of 
nitric oxide (NO), an essential substance in regulating vascular tone, triggering vasodilation 
and increasing blood flow (Wu & Meininger, 2000).  
 
Despite the fact that L-arginine is already stored in significant intracellular amounts 
(Hambrecht et al. 2000), previous literature has indicated that L-arginine supplementation is 
associated with improvements in endothelial function, for example, increasing blood flow by 
increasing arterial diameter via NO-mediated vasodilation (Bailey et al. 2000; Lerman et al. 
1998). In theory, increasing blood flow will then in turn improve exercise performance via an 
increased rate of oxygen and substrate delivery (Tang et al. 2011), glucose uptake, and 
removal of waste exercise bi-products. The aforementioned physiological pathways of L-
arginine would therefore reasonably suggest that supplemental L-arginine could improve 
exercise performance (Campbell, La Bounty & Roberts, 2004), yet the available literature 
evidence is limited and conflicting.  
 
The reported physiological and biochemical effects of L-arginine have served as the 
rationale behind the development and marketing of a number of NO stimulating dietary 
supplements to elite athletes (Campbell et al. 2006). Such supplements profess to augment 
NO production, therefore improving blood flow to muscle during training, and in turn, leading 
to greater training adaptations. Consequently, in recent years, professional sports individuals 
have begun to use L-arginine supplementation prior to competition as an ergogenic aid 
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(Campbell et al. 2006) Indeed, supplementation with L-arginine and similar “NO boosters” 
has soared in popularity over the last decade (Campbell et al. 2006), despite the fact that 
there is an overall lack of supportive data in healthy human cohorts, as ergogenic potential 
remains controversial and inconclusive (Bailey et al. 2010; Liu, Hung, Jang & Chang. 2010).  
 
While L-arginine supplementation has been compellingly established to improve exercise 
tolerance in patient populations (Hambrecht et al. 2000; Ceremuzynski, Chamiec & 
Herbaczynska-Cedro, 1997), the evidence in healthy humans, and athletic populations, is 
less consistent and often conflicting. Specifically, improvements in repeated sprint 
performance (ARG -1 ± 9 vs PLA -47 ± 18 W, power output decrease between sprints, 
Buford & Koch, 2004); time to exhaustion (ARG 707 ± 232 vs PLA 562 ± 145 seconds, 
Bailey et al. 2010); cycling time trial performance (ARG 32:04 ± 1:38 vs PLA 32:38 ± 1:50 
min, Ranchordas & Whitehead, 2011); muscular power and fatigue resistance (ARG 8.82 ± 
7.33 vs PLA 2.67 ± 9.11 kg change in 1RM, Campbell et al. 2006) have each been observed 
in studies following L-arginine supplementation; yet the supportive evidence-base is limited 
and conflicted. Equally, supplementation with L-arginine has been shown to be ineffective in 
improving muscular endurance and resistance to fatigue (Wax, Kavazis, Webb & Brown, 
2012; Greer & Jones, 2011; Willoughby et al. 2011). 
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Aims & Hypotheses 
 
In the absence of fully substantiated claims from supplement manufacturers supporting the 
notion that arginine-containing supplements indeed provide ergogenic benefit; the aim of this 
study was therefore to determine the effects of acute supplementation of commercially 
available L-arginine on cycling time trial performance, heart rate (HR) response, volitionally 
selected power output (PO) and rating of perceived exertion (RPE). The following 
hypotheses were made prior to the commencement of the study. Acute consumption of 
arginine pre-training will significantly: 1) improve cycling time trial performance, 2) enhance 
power output, 3) reduce perceived exertion, and 4) reduce heart rate. 
 
Methods 
 
Participants: 
Twelve recreationally trained, young adult males volunteered to participate in three trials in a 
double-blind, repeated-measures design. The sample size was justified through the use of a 
sample size power calculation to achieve a power of 0.8 (Appendix 1). The definition of 
‘recreationally trained’ was adopted from Gearhart (2008) and, as such, inclusion criteria 
was anyone that was not training for a specific event or activity, but was 
training ‘‘recreationally’’, on a regular, planned basis, for health, cosmetic or other benefits. 
Exclusion criteria for participants was any pre-existing illness, ailment or medical condition, 
screened before the commencment of the study via a health screening questionaire 
(Appendix 2). All participants provided written, informed consent and ethical approval was 
obtained from the Faculty of Applied and Health Sciences ethics committee at the University 
of Chester.  
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Procedures: 
This study utilised a repeated measures design in which each participant was required to 
attend the gym facility on three separate occasions. Upon the first visit to the gym, 
participants were provided a thorough familiarisation of procedures, anthropometric 
measurements of height and weight were taken, and subsequently a 10-mile cycling time 
trial was performed on a cycle ergometer (Corival Ergometer, Lode, Netherlands) to 
establish baseline characteristics. No pre-test beverage was provided in this control (CON) 
trial.  
 
The use of time-trial as a measure of exercise performance was justified by the work of 
Jeukendrup, Saris, Brouns and Kester (1996) who validated that tests to exhaustion have a 
much lower reproducibility, and therefore reliability, than time-trial protocols, which are 
therefore a better solution for performance evaluation.  
 
Throughout the time trial, participants volitionally selected a level of PO, using the bike’s 
keypad, pressing ‘up’ to increase the load, and ‘down’ to reduce it. Cycling time trial 
completion time, PO, HR and RPE (via Borg scale) were recorded throughout, the latter 
three measures being taken by the researcher at pre-determined time intervals of 5 minutes 
until test completion. All measures were concealed from participants at all times. 
 
During the next two testing sessions, participants consumed either a pre-prepared 500ml 
placebo (PLA) or an L-arginine beverage containing 8g L-arginine (ARG). In PLA, the drink 
consisted of 400ml water and 100ml fruit juice concentrate (Robinson’s “Apple and 
Blackcurrent - No Added Sugar”, Britvic PLC, UK). In the ARG condition, the drink was the 
same but also contained 8g of commercially available arginine in powdered form (Primary 
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Arginine ®, Maximuscle Ltd, Hemel Hempstead, UK). This dose had previously been shown 
to be 'safe and well tolerated' (Campbell et al. 2006) and a seven-day washout period 
seperated the trials, in line with previous work (Greer & Jones, 2011).  
 
Supplements were ingested immediately upon arrival at the gym and 45 minutes prior to 
exercise, in line with previous protocols (Wax et al. 2012; Buford & Koch, 2004). They were 
the same colour, texture and taste, and were administered in a double-blind fashion, with 
beverages taken in a randomised counter-balanced manner to prevent a learning effect 
taking place. Following ingestion of the supplement, participants rested during a full briefing 
and equipment set-up and then prepared for testing, prior to a short warm-up and 
subsequently a 10-mile cycling time trial. 
 
Participants were instructed to refrain from caffeine and alcohol in the 24 hours preceding 
each test as these have been previously demonstrated to effect exercise capacity and 
performance variables (Cox et al. 2002). All tests were performed at the same time of day (± 
2 hours) for each participant to minimise the effects of biological variation on physiological 
responses and exercise performance (Atkinson & Reilly, 1996). 
Data Analysis: 
Statistical analysis was performed using commercially available software, SPSS 19 (SPSS 
Inc., Chicago, IL, USA). Statistical significance was accepted when p < 0.05 and data are 
presented as mean ± SD. Following a check on data distribution normality via the Shapiro-
Wilk statistic, time-trial performance, HR, PO and RPE, were each assessed by use of 
separate One-way (Repeated Measures) ANOVAs. Paired t-tests were used Post Hoc to 
identify where significant differences lay, followed by Bonferroni multiple comparison 
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adjustment as appropriate to reduce the potential for a type 1 statistical error. Mauchly’s test 
of sphericity was used to confirm homogeneity. 
 
Results 
 
Participant Characteristics: 
All twelve volunteers met the inclusion criteria and completed all testing procedures. 
Participants had a mean age, weight and height of 22.3 ± 4.1 years, 79.3 ± 7.9 kg, 180.9 ± 
2.3 cm, respectively. Participant compliance with supplement ingestion was 100%. 
 
Time Trial Performance: 
In terms of 10-mile cycling time-trial performance, there was no significant difference (p = 
0.643) between the conditions (CON 29:49 ± 2:19 vs ARG 29:49 ± 3:18 vs PLA 29:30 ± 2:39 
minutes). There was a mean 19 second reduction in time-trial completion time in the PLA 
condition, but this was deemed insignificant when compared to the CON (p = 0.276) and 
ARG (p = 0.394) trials (Fig. 1). 
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Figure 1: Time to completions (seconds) for 10-mile cycling time trial on Corival Ergometer. Data are 
displayed as mean ± SD. There was no significant different difference between the conditions (p = 0.643). 
 
 
Heart Rate: 
HR increases linearly as exercise intensity increases. While the present findings reflect this 
relationship across all conditions (Fig. 2), HR responses were not significantly different (p = 
0.129) between conditions (CON 169.2 ± 11.3 vs ARG 167.2 ± 10.8 vs PLA 166.3 ± 7.8 
bpm). 
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Figure 2: Heart rate (bpm) responses throughout duration of time-trial protocol. Data are presented as 
mean ± SD. There was no significant difference between the conditions (p = 0.129). 
 
Power Output: 
No significant difference (p = 0.276) was observed between conditions (CON 119.3 ± 8.7 vs 
ARG 120.1 ± 7.7 vs PLA 121.2 ± 6.2 W) in terms of self-selected PO (Fig. 3). 
 
Rating of Perceived Exertion: 
Significant difference (p = 0.033) was observed between conditions (Fig. 4) (CON 15.6 ± 1.6 
vs ARG 15.2 ± 2.0 vs PLA 15.0 ± 1.7). Post Hoc analysis via multiple paired t-tests revealed 
that this difference lay between CON & PLA (p = 0.0005), while no significant difference was 
observed between CON & ARG (p = 0.148) or ARG & PLA (p = 0.149). After a Bonferroni 
adjustment for multiple comparisons, statistical significance was accepted as p < 0.017. 
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Figure 3: Self-selected power output (W) values throughout duration of time-trial protocol. Values were 
hidden from participants throughout by taping across the bike’s output display. Data are presented as 
mean ± SD. There was no significant difference between the conditions (p = 0.276). 
 
Figure 4: RPE responses throughout the duration of the time-trial protocol. Data are presented as mean ± 
SD. There was significant difference between CON & PLA (p = 0.0005) but no significant difference was 
observed between the experimental trials ARG & PLA (p = 0.149) or between CON & ARG (p = 0.148). 
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Discussion 
 
The main finding of this study was that acute supplementation with L-arginine, 45 minutes 
prior to exercise, provided no ergogenic benefit. These results bring into question the 
ergogenic potential of arginine in healthy young men. The ergogenic potential of arginine-
based supplementation remains equivocal in the literature. 
 
Previously, improvements in sprint performance (Buford & Koch, 2004), time to exhaustion 
during high intensity cycling to fatigue (Bailey et al. 2010), muscular power and fatigue 
resistance (Campbell et al. 2006) have each been observed in studies following L-arginine 
supplementation. However, concurrent with the findings of the present study, Greer & Jones 
(2011) did not observe any ergogenic effect on muscular endurance following acute 
supplementation with AAKG; neither did Wax et al. (2012) find any improvement in muscular 
performance following an acute dose of AAKG in either trained and untrained individuals.  
 
A very relevant, recent study (Ranchordas & Whitehead, 2011) did observe improvements 
(ARG 32:04 ± 1:38 vs PLA 32:38 ± 1:50 min) in 20km cycling time trial performance in highly 
trained, competitive male cyclists, following a 3 day supplementation with L-arginine, 
however, the small sample size (n=6) makes it difficult to draw conclusions. 
 
Although arginine-containing ‘NO stimulating’ supplements are marketed to increase 
exercise performance, this study does not support this contention with acute ingestion. It is 
true that the major advertised ergogenic benefit of arginine-based supplements rests on the 
assumption of augmented production of NO. However, it should be noted that this is not a 
foregone conclusion (Greer & Jones, 2011). Indeed, Tang et al. (2010) reported that, despite 
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a 300% increase in plasma arginine levels, arginine supplementation did not stimulate an 
increase in NO synthesis or muscle blood flow in young men, at rest or after resistance 
exercise (p > 0.05). 
 
Likewise, Willoughby et al. (2011) observed that 7-days L-arginine supplementation provided 
no benefit in terms of hemodynamics or blood flow. Analysis revealed that although heart 
rate, systolic and diastolic blood pressure and MAP each increased significantly (p = 0.001) 
with a resistance exercise protocol, there was no significant difference (p > 0.05) between 
ARG and PLA groups. Furthermore, although plasma-L-arginine significantly increased in 
the ARG group, was no significant difference between groups (p = 0.73) in levels of serum 
NOx (nitrites/nitrates). Likewise, there was no significant difference between ARG and PLA 
in terms of brachial-artery blood flow responses (p = 0.14), which brings into question the 
very rationale of L-arginine ergogenics.  
 
There is a recent selection of literature in support of the findings of Willoughby et al. (2011). 
For example, it has been shown that single-doses of three separate alleged nitric-oxide-
inducing supplements (each containing L-arginine) were each ineffective at increasing 
circulating nitric oxide levels and blood flow in response to resistance exercise (Bloomer et 
al. 2010). Similarly, work by Fahs, Heffernan & Fernhall (2009) observed that there was no 
significant change in blood flow or hemodynamic and vascular responses when 7g of L-
arginine was given acutely, immediately before resistance exercise. 
 
The lack of ergogenic effect in the present study may speculatively be as a result of the 
amount of L-arginine ingested. According to Willoughby et al. (2011), there is no empirical 
evidence demonstrating any acute vasodilatory effects with doses less than 15g/day, 
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Moreover, the issue of L-arginine’s bioavailability must be taken into consideration. It has 
previously been suggested that as much as 50% of L-arginine consumed orally is 
metabolised in the liver (Castillo et al. 1995). Indeed, L-arginine bioavailability following oral 
administration has been found to be approximately 68% (Bode-Boger et al. 1998). As a 
result, it is conceivable to conclude that lower doses of L-arginine may lack the bioavailability 
required to augment nitric oxide production. Therefore it is plausible to suggest that the lack 
of ergogenic effect observed in the present study may be as a consequence of an 
inadequate amount of bioavailable L-arginine. 
 
The lack of effect demonstrated by the present study, and previously by Greer & Jones 
(2011) and Wax et al. (2012) suggest that small, acute doses of L-arginine may be 
insufficient in harnessing ergogenic benefits. However, larger doses and extended loading 
protocols have also proved unsuccessful (Willoughby et al. 2011). This brings into question 
the rationale for pre-exercise supplementation with arginine-based products. 
 
It is conceivable to speculate that the lack of effect observed on PO and HR in the present 
study is consequential of a lack of effect on nitric oxide stimulation, as aforementioned. 
However, no assessment on nitric oxide levels, or blood flow was conducted in the present 
study, a potential weakness to the study design.  
 
One surprising finding in the present study was the significant difference (p = 0.0005) in 
participant RPE responses observed between CON and PLA trials. No significant difference 
was observed between CON & ARG (p = 0.148) or ARG & PLA (p = 0.149). It is speculated, 
however, that this difference could be accounted for merely by placebo effect, and 
emphasises a further potential limitation within the study design. The possibility of placebo 
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effect was not completely alleviated, owing to the complete absence of a beverage in the 
initial CON condition. 
 
As demonstrated, the ergogenic potential of L-arginine-based supplementation remains 
equivocal in the literature, and the need for further research is therefore well established. 
Experimentation with higher dosages, perhaps as high as 30g as hypothesised by Bode-
Boger et al. (1998) may be justified. However, concerns with tolerance and aforementioned 
side effects may arise. 
 
Indeed, arginine doses of 10g have been associated with gastrointestinal pain and diarrhoea 
(Robinson, Sewell & Greenhaff, 2003). Meanwhile, Prosser et al. (2009) have reported the 
adverse side effects associated with cases of hospital admittance following the consumption 
of L-arginine containing supplements. The possible adverse health effects should not be 
neglected or minimalised, and with ergogenic benefit equivocal, Industry directives to 
consume doses of arginine before exercise may therefore be unwarranted (Greer & Jones, 
2011). 
 
In summary, the present study provides data herein that somewhat refute the claim that 
arginine-based supplements are effective ‘pre-trainers’ for enhancing exercise performance. 
No significant differences were observed between CON, ARG or PLA conditions in terms of 
cycling time-trial performance or performance variables of heart rate, power output or RPE. 
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Practical Applications 
 
Arginine-based ‘NO boosting’ supplements are marketed to increase muscular endurance 
and benefit exercise capacity. However, this study is in agreement with previous work (Greer 
& Jones, 2011; Wax et al. 2012; Willoughby et al. 2011) in not supporting this contention 
with acute ingestion. 
 
A review of the literature suggests that L-arginine can indeed provide an alternative 
therapeutic approach in cases of endothelial dysfunction (Hambrecht et al. 2000). Yet, while 
there is compelling evidence for the potential benefits of supplemental L-arginine 
administration in these patient populations, the evidence in healthy humans is less 
consistent. Evidence such as that provided by the present study brings into question the 
ergogenic potential of L-arginine supplementation and therefore the efficacy of L-arginine 
products in healthy humans. 
 
With concerns regarding possible adverse health effects and ingestion discomforts 
previously reported (Prosser et al. 2009; Robinson et al. 2003), and ergogenic potential 
remaining unclear, industry instructions to consume large doses of arginine before exercise 
may therefore be unwarranted (Greer & Jones, 2011), and the rationale for supplementation 
should be questioned. 
 
 
 
 
20 
 
References 
 
Atkinson, G. & Reilly, T. (1996). Circadian variation in sports performance. Sports Medicine. 
21(4): 292-312 
 
Bailey, S. J., Winyard, P. G., Vanhatalo, A., Blackwell, J. R., DiMenna, F. J., Wilkerson, D. P. 
& Jones, A. M. (2010). Acute L-arginine supplementation reduces the O2 cost of moderate-
intensity exercise and enhances high-intensity exercise tolerance. Journal of Applied 
Physiology. 109:1394-1403 
 
Bloomer, R. J., Farney, T. M., Trepanowski, J. F., McCarthy, C. G., Canale, R. E., & 
Schilling, B. K. (2010). Comparison of pre-workout nitric oxide stimulating dietary 
supplements on skeletal muscle oxygen saturation, blood nitrate/nitrite, lipid peroxidation, 
and upper body exercise performance in resistance training men. Journal of International 
Society of Sports Nutrition. 7, 16-30 
 
Bode-Boger, S. M., Boger, R. H., Galland, A., Tsikas, D. & Frolich, J. C. (1998). L-arginine 
induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. 
British Journal of Clinical Pharmacology. 46, 489-497 
 
Buford, B. N. & Koch, A.J. (2004). Glycine-arginine-α-ketoisocaproic acid improves 
performance of repeated cycling sprints. Medicine & Science in Sports & Exercise. 36: 583-
587 
 
Campbell, B. I., La Bounty, P. M. & Roberts, M. (2004). The Ergogenic Potential of Arginine. 
Journal of the International Society of Sports Nutrition. 1(2):35-38 
 
Campbell, B. I., Roberts, M., Kerksick, C., Wilborn, C., Marcello, B., Taylor, L., Nassar, E., 
Leutholtz, B., Bowden, R., Rasmussen, C., Greenwood, M. & Kreider, R. (2006). 
21 
 
Pharmacokinetics, safety, and effects on exercise performance of L-arginine a-ketoglutarate 
in trained adult men. Nutrition. 22. 872-881 
 
Castillo, L., Sánchez, M., Vogt, J., Chapman, T. E., DeRojas-Walker, T. C., Tannenbaum, S. 
R., Ajami, A. M. & Young, V. R. (1995). Plasma arginine, citrulline, and ornithine kinetics in 
adults, with observations on nitric oxide synthesis. American Journal of Physiology, 
Endocrinology and Metabolism. 268: E360–E367 
 
Ceremuzynski, L., Chamiec, T. & Herbaczynska-Cedro, K. (1997). Effect of Supplemental 
Oral L-Arginine on Exercise Capacity in Patients with Stable Angina Pectoris. American 
Journal of Cardiology. 80: 331-333 
 
Cox, G. R., Desbrow, B., Montgomery, P. G., Anderson, M. E., Bruce, C. R., Macrides, T. A., 
Martin, D. T., Moquin, A., Roberts, A., Hawley, J. A. & Burke, L. M. (2002). Effect of different 
protocols of caffeine intake on metabolism and endurance performance. Journal of Applied 
Physiology. 93: 990-999 
 
Fahs, C. A., Heffernan, K. S. & Fernhall, B. (2009). Hemodynamic and vascular response to 
resistance exercise with L-arginine. Medicine & Science in Sports & Exercise. 41: 4, 773-779 
 
Gearhart, R. F. (2008). Ratings of perceived exertion and oxygen consumption during 
maximal, graded, treadmill exercise following different anchoring procedures. European 
Journal of Sport Science. 8:1, 35-40 
 
Greer, B. K. & Jones, B. T. (2011). Acute Arginine Supplementation Fails To Improve Muscle 
Endurance Or Affect Blood Pressure Responses To Resistance Training. Journal of Strength 
& Conditioning Research. 25(7), 1789-1794 
 
22 
 
Hambrecht, R., Hilbrich, L., Erbs, S., Gielen, S., Fiehn, E., Schoene, N. & Schuler, G. 
(2000). Correction of Endothelial Dysfunction in Chronic Heart Failure: Additional Effects of 
Exercise Training and Oral L-Arginine Supplementation. Journal of the American College of 
Cardiology. 35: 706-713 
 
Jeukendrup, A., Saris, W. H. M., Brouns, F. & Kester, A. D. M. (1996). A new validated 
endurance performance test. Medicine & Science in Sports & Exercise. 28(2), p266-270 
 
Lerman, A., Burnett, J. C., Higano, S. T., McKinley, L. J. & Holmes, D. J. (1997). Long-term 
L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in 
Humans. Circulation. 97: 2123-2128 
 
Liu, T. H., Hung, W., Jang, T. R. & Chang, C. K. (2010). Effect of Short-term Arginine 
Supplementation on Vasodilation and Performance in Intermittent Exercise in Judo Athletes. 
International Journal of Sport and Exercise Science, 1(2): 7-12 
 
Morris, S. M. (2006). Arginine: beyond protein. American Journal Clinical Nutrition. 83, 508S-
512S 
 
Prosser, J. M., Majlesi, N., Chan, G. M., Olsen, D., Hoffman, R. S. & Nelson, L. S. 
(2009). Adverse effects associated with arginine alpha-ketoglutarate containing 
supplements. Human & Experimental Toxicology. 28(5), 259-262 
 
Ranchordas, M. K. & Whitehead, T. (2011). Effect of acute L-arginine supplementation on 
20km time trial performance in competitive male cyclists. British Journal of Sports Medicine. 
doi: 10.1136/bjsports-2011-090606.35 
 
23 
 
Robinson, T. M., Sewell, D. A. & Greenhaff, P. L. (2003). L-arginine ingestion after rest and 
exercise: Effects on Glucose Disposal. Medicine & Science in Sports & Exercise. 35: 8, 
1309-1315 
 
Tang, J. E., Lysecki, P. J., Manolakos, J. J., MacDonald, M. J., Tarnopolsky, M. A. & Phillips, 
S. M. (2011). Bolus Arginine Supplementation Affects neither Muscle Blood Flow nor Muscle 
Protein Synthesis in Young Men at Rest or After Resistance Exercise. The Journal of 
Nutrition. 141(2), 195-200 
 
Wax, B., Kavazis, A. N., Webb, H. E. & Brown, S. P. (2012). Acute L-arginine alpha 
ketoglutarate supplementation fails to improve muscular performance in resistance trained 
and untrained men. Journal of the International Society of Sports Nutrition. doi: 
10.1186/1550-2783-9-17  
 
Willoughby, D. S., Boucher, T., Reid, J., Skelton, G. & Clark, M. (2011). Effects of 7 days of 
arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide 
metabolites and asymmetric dimethyl arginine after resistance exercise. International Journal 
of Sports Nutrition and Exercise Metabolism. 21: 291-299  
 
Wu, G. & Meininger, C. J. (2000). Arginine Nutrition and Cardiovascular Function. Journal of 
Nutrition. 130: 2626-2629 
 
 
 
 
 
 
 
 Append
 
 
 
 
 
 
 
 
 
 
 
ix 1 – Sample Size Power Calculation 
 
24 
 
 Append
 
 
The eff
 
 
Name:__
 
 
Contact 
 
In  order
potentia
answer t
 
1. Has 
perf
 
2. Do y
 
3. In th
activ
ix 2 – Pre-t
ects of acute
_________
number:___
  to  ensure 
l participan
o the follow
your doctor
orm physica
ou feel pain
e past mon
ity? 
est Health 
 arginine su
__________
__________
that  this  st
t  is  screene
ing question
 ever said th
l activity rec
 in the chest
th, have yo
Screening Q
Pre‐te
pplementat
Resea
__________
__________
udy  is  as  sa
d  for any  fa
s: 
at you have
ommended 
 when you p
u had chest 
uestionna
st Question
ion on 10 m
adult males
rcher:  Sa
 
__  Test dat
_____ Date
fe  and  accu
ctors  that m
 a heart con
by a doctor?
erform phy
pain when 
ire 
naire 
 
ile cycling t
 
m Gill 
e:_________
 of birth:___
rate  as  pos
ay  influenc
dition and t
 
sical activity
you were no
 
ime‐trial per
_______ 
________ 
sible,  it  is  i
e  the  study
hat     you sh
? 
t performin
formance in
mportant  t
.   Please  cir
ould only 
g physical 
25 
 young 
hat  each 
cle  your 
YE
YE
YE
S/NO 
S/NO 
S/NO 
26 
 
 
4. Do you lose your balance because of dizziness or do you ever lose consciousness? 
 
5. Do you have bone or joint problems (e.g. back, knee or hip) that could be made worse 
by a change in your physical activity? 
 
6. Is your doctor currently prescribing drugs for your blood pressure or heart condition? 
 
7. Have you injured your hip, knee or ankle joint in the last six months? 
 
8. Do you know of any other reason why you should not participate in physical activity? 
 
Thank you  for taking your time to  fill  in this  form.  If you have answered  ‘yes’ to any of the above 
questions, unfortunately you will not be able to participate in this study. 
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